Ris­ing from the IL-2 ash­es and dras­tic re­org, Nek­tar in merg­er talks with PureTech

The ques­tion has hung around the air for months now: Where will Nek­tar, the one-time high-fly­ing biotech once best known for its Bris­tol My­ers Squibb al­liance, go af­ter the multi­bil­lion-dol­lar IL-2 pro­gram fell apart?

What about a merg­er?

Lon­don-based PureTech Health sur­prised the in­dus­try with a late Thurs­day state­ment con­firm­ing that “it has ex­changed in­dica­tive, non-bind­ing pro­pos­als with Nek­tar Ther­a­peu­tics” re­gard­ing a pos­si­ble com­bi­na­tion, “which may in­clude, amongst oth­er things, an of­fer for share cap­i­tal of PureTech.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER